-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L3GzgvE4lOL8jB2BnMYZANp6vx/hAhczzvC+A1dCUIIgQFbUF4sqbqwlwyehoDHR FCswvbzvy07KfcrAWPVxsw== 0000936392-06-000333.txt : 20060411 0000936392-06-000333.hdr.sgml : 20060411 20060411165337 ACCESSION NUMBER: 0000936392-06-000333 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060411 ITEM INFORMATION: Other Events FILED AS OF DATE: 20060411 DATE AS OF CHANGE: 20060411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AASTROM BIOSCIENCES INC CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22025 FILM NUMBER: 06754080 BUSINESS ADDRESS: STREET 1: 24 FRANKL LLOYD WRIGHT DR STREET 2: PO BOX 376 CITY: ANN ARBOR STATE: MI ZIP: 48106 BUSINESS PHONE: 7349305555 8-K 1 a19521e8vk.htm FORM 8-K Aastrom Biosciences, Inc.
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event reported): April 11, 2006
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
         
Michigan
(State or other jurisdiction of
incorporation) 		  0-22025
(Commission File No.) 		  94-3096597
(I.R.S. Employer Identification
No.)
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 48106
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(734) 930-5555
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01. Other Events.
SIGNATURES

Table of Contents

Item 8.01. Other Events.
     On April 11, 2006 Aastrom Biosciences, Inc. (“Aastrom”) closed its previously announced registered direct offering of 15,943,750 shares of Aastrom’s common stock to certain institutional investors at a price of $1.60 per share. The aggregate gross proceeds from the direct offering were approximately $25.5 million. The net proceeds, after deducting the placement agents’ fee and other estimated offering expenses, were approximately $23.8 million.

2

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 11, 2006
         
  AASTROM BIOSCIENCES, INC.
 		  
  By:   /s/ Gerald D. Brennan, Jr.    
    Gerald D. Brennan, Jr.   
    Vice President, Administrative and
Financial Operations, CFO 		  
 

3

-----END PRIVACY-ENHANCED MESSAGE-----